news paper icon

Analyzed News

UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year. [Source]

Publication Date:

Origin: reuters.com

Category: companyNews

Topics: rival, priced, treatment, cancer, vitrakvi

Source Link: http://feeds.reuters.com/~r/reuters/companyNews/~3/1A1TAiUCboA/update-2-roche-cancer-treatment-priced-at-17050-a-month-lower-than-rival-vitrakvi-idUSL4N25C2YR

Related Articles